---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-012545"
form_type: "8-K"
ticker: "ERNA"
cik: "0000748592"
company_name: "Ernexa Therapeutics Inc."
filed_at: "2023-03-20T23:59:59+00:00"
generated_at: "2026-06-17T23:20:08.689159+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Eterna Therapeutics posts FY2022 net loss $24.6M; licenses iPSC tech to Lineage, subleases BMS space

## Summary
- Net loss for Q4 2022 was $4.5M ($1.24 per share); full year net loss $24.6M ($8.06 per share).
- Cash and restricted cash $15.5M as of Dec 31, 2022; $4.1M restricted for BMS sublease.
- Entered income-generating license agreement with Lineage Cell Therapeutics for gene-edited iPSC lines for neurology indications.
- Subleased 45,000 sq. ft. from BMS at Cambridge Crossing; BMS provides $8.6M for build-out.
- Appointed Matt Angel, Ph.D. as permanent CEO and President (previously interim).

## SEC filing metadata
- accession: 0001140361-23-012545
- form_type: 8-K
- ticker: ERNA
- cik: 0000748592
- company_name: Ernexa Therapeutics Inc.
- filed_at: 2023-03-20T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/748592/000114036123012545/0001140361-23-012545-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/748592/000114036123012545/brhc10050022_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-012545
- JSON: https://secwatch.observer/filing/0001140361-23-012545.json
- Plain text: https://secwatch.observer/filing/0001140361-23-012545.txt

## Key facts
- Earnings Releases
  Ernexa Therapeutics Inc. reported full year of 2022 results: net income For the full year of 2022, net loss was $24.6 million, or $8.06 per share., EPS $8.06 per share.
  - Period: full year of 2022
  - Net income: For the full year of 2022, net loss was $24.6 million, or $8.06 per share.
  - EPS: $8.06 per share
  - Result: reported results
  source text: For the full year of 2022, net loss was $24.6 million, or $8.06 per share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/748592/000114036123012545/0001140361-23-012545-index.htm
- Earnings Releases
  Ernexa Therapeutics Inc. reported fourth quarter of 2022 results: net income Net loss for the fourth quarter of 2022 was $4.5 million, or $1.24 per share, EPS $1.24 per share.
  - Period: fourth quarter of 2022
  - Net income: Net loss for the fourth quarter of 2022 was $4.5 million, or $1.24 per share
  - EPS: $1.24 per share
  - Result: reported results
  source text: Net loss for the fourth quarter of 2022 was $4.5 million, or $1.24 per share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/748592/000114036123012545/0001140361-23-012545-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.